Matthew Mosior
Overview
Explore the profile of Matthew Mosior including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez F, Fisk B, McMichael J, Mosior M, Foltz J, Skidmore Z, et al.
Cancer Res Commun
. 2023 Nov;
3(11):2312-2330.
PMID: 37910143
Significance: Our data demonstrate the utility of ultra-deep exome sequencing in uncovering somatic variants in Hodgkin lymphoma, creating new opportunities to define the genes that are recurrently mutated in this...
2.
Freshour S, Chen T, Fisk B, Shen H, Mosior M, Skidmore Z, et al.
iScience
. 2023 Oct;
26(10):107937.
PMID: 37810214
To explore mechanisms of response to combined PD-1/CTLA-4 immune checkpoint blockade (ICB) treatment in individual cell types, we generated scRNA-seq using a mouse model of invasive urothelial carcinoma with three...
3.
Russler-Germain D, Krysiak K, Ramirez C, Mosior M, Watkins M, Gomez F, et al.
Blood Adv
. 2023 Jul;
7(18):5524-5539.
PMID: 37493986
Follicular lymphoma (FL) is clinically heterogeneous, with select patients tolerating extended watch-and-wait, whereas others require prompt treatment, suffer progression of disease within 24 months of treatment (POD24), and/or experience aggressive...
4.
Freshour S, Chen T, Fisk B, Shen H, Mosior M, Skidmore Z, et al.
bioRxiv
. 2023 Apr;
PMID: 37034778
To explore mechanisms of response to combined PD-1/CTLA-4 immune checkpoint blockade (ICB) treatment in individual cell types, we generated scRNA-seq using a mouse model of invasive urothelial carcinoma with three...
5.
Berrien-Elliott M, Foltz J, Russler-Germain D, Neal C, Tran J, Gang M, et al.
Sci Transl Med
. 2022 Feb;
14(633):eabm1375.
PMID: 35196021
Natural killer (NK) cells are innate lymphoid cells that eliminate cancer cells, produce cytokines, and are being investigated as a nascent cellular immunotherapy. Impaired NK cell function, expansion, and persistence...
6.
Ward J, Berrien-Elliott M, Gomez F, Luo J, Becker-Hapak M, Cashen A, et al.
Blood
. 2021 Nov;
139(13):1999-2010.
PMID: 34780623
New therapies are needed for patients with relapsed/refractory (rel/ref) diffuse large B-cell lymphoma (DLBCL) who do not benefit from or are ineligible for stem cell transplant and chimeric antigen receptor...
7.
Khanna A, Larson D, Nonavinkere Srivatsan S, Mosior M, Abbott T, Kiwala S, et al.
ArXiv
. 2021 Aug;
PMID: 34341766
Bam-readcount is a utility for generating low-level information about sequencing data at specific nucleotide positions. Originally designed to help filter genomic mutation calls, the metrics it outputs are useful as...
8.
Foltz J, Hess B, Bachanova V, Bartlett N, Berrien-Elliott M, McClain E, et al.
Clin Cancer Res
. 2021 Apr;
27(12):3339-3350.
PMID: 33832946
Purpose: N-803 is an IL15 receptor superagonist complex, designed to optimize persistence and trans-presentation, thereby activating and expanding natural killer (NK) cells and CD8 T cells. Monoclonal antibodies (mAbs) direct...
9.
Harris Z, Dhungel E, Mosior M, Ahn T
Biol Direct
. 2019 Aug;
14(1):12.
PMID: 31370905
Background: Metagenomics is the application of modern genomic techniques to investigate the members of a microbial community directly in their natural environments and is widely used in many studies to...